Key Segmentation
By Technology
-
RNA-Targeted Therapeutics
-
Gene Therapies
-
Genome Editing Therapies
-
Epigenetic & microRNA Modulating Therapies
By Application
-
Genetic Disorders
-
Cancer
-
Infectious Diseases
-
Autoimmune Disorders
By End User
-
Hospitals & Clinics
-
Academic & Research Institutes
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Leading companies include Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Moderna Inc., BioNTech SE, and Novartis Pharma AG, among other major RNA therapeutics and genome editing biotechnology companies.
Opportunities include continued development of extrahepatic delivery systems reaching the central nervous system and muscle, rapid expansion of mRNA and RNA interference cancer immunotherapy pipelines, and growing CDMO investment in vertically integrated manufacturing capability
Growth is driven by increasing prevalence of genetic and chronic diseases, continued advances in genomics and molecular biology, growing R&D investment following mRNA platform validation, and rising demand for personalized precision medicine approaches.
RNA-Targeted Therapeutics dominates by technology with approximately 54.6% share, Genetic Disorders dominates by application with roughly 34.8% share, and Hospitals & Clinics dominates by end user with about 48.3% share; Genome Editing Therapies, Cancer, and Academic & Research Institutes are the fastest-growing segments within their respective categories.
North America is the largest regional market with approximately 46.0% share, led by the United States, while Asia Pacific, led by China, is the fastest-growing region through 2035.
